Simplicity Wealth LLC Purchases 19,800 Shares of Boston Scientific Corporation $BSX

Key Points

• Simplicity Wealth LLC significantly increased its holdings in Boston Scientific Corporation, acquiring 19,800 additional shares, bringing its total ownership to 40,214 shares valued at approximately $4.3 million.
• Multiple analysts have upgraded their price targets for Boston Scientific, with recent forecasts ranging from $121.00 to $136.00, reflecting positive sentiment on the company's stock.
• Boston Scientific reported a 22.8% year-over-year increase in revenue for the latest quarter, with earnings per share of $0.75, beating analysts' expectations.

Simplicity Wealth LLC raised its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 97.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,214 shares of the medical equipment provider's stock after purchasing an additional 19,800 shares during the period. Simplicity Wealth LLC's holdings in Boston Scientific were worth $4,319,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. GAMMA Investing LLC raised its position in Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider's stock worth $3,167,000 after purchasing an additional 3,932 shares during the last quarter. Bank of New Hampshire raised its position in Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider's stock worth $2,119,000 after purchasing an additional 16,699 shares during the last quarter. MRA Advisory Group bought a new position in Boston Scientific during the 2nd quarter worth $273,000. NS Partners Ltd raised its position in Boston Scientific by 1.6% during the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock worth $37,143,000 after purchasing an additional 5,704 shares during the last quarter. Finally, Neville Rodie & Shaw Inc. raised its position in Boston Scientific by 95.9% during the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider's stock worth $4,883,000 after purchasing an additional 22,255 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on BSX shares. BTIG Research raised their target price on Boston Scientific from $127.00 to $132.00 and gave the stock a "buy" rating in a research report on Wednesday. Barclays lifted their price objective on Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research report on Thursday. Needham & Company LLC reissued a "buy" rating and issued a $121.00 price objective on shares of Boston Scientific in a research report on Wednesday. Robert W. Baird lifted their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, Oppenheimer raised Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $120.79.

Boston Scientific Stock Performance

Shares of BSX opened at $97.30 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock has a 50-day moving average of $102.93 and a 200-day moving average of $102.06. The company has a market cap of $144.17 billion, a PE ratio of 57.91, a P/E/G ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.